The antagonism of push and pull strategies, and the current funding campaigns to fight orphan diseases
We argue that an increase in investments in R&D for innovative treatments to eradicate neglected diseases in developing countries leads to a rational decrease in investments in available treatment technologies. In a formal model where the government of a developing country seeks to optimally allocate public resources, we show that the higher the odds of appearance of an innovative treatment, as occurring when investments in R&D increase, the lower the optimal provision of current treatments and other health expenditures. We also show that this phenomenon is aggravated when the opportunity cost of investments in current treatments increases. This implies that welfare in developing countries deteriorates as innovative treatments are more likely to become available. We also describe an insurance scheme that remedies these issues, and that leads to Pareto-optimal allocations regardless of the investment level in R&D for innovative treatments.
Volume (Year): 72 (2011)
Issue (Month): 2 (January)
|Contact details of provider:|| Web page: http://www.elsevier.com/wps/find/journaldescription.cws_home/315/description#description|
|Order Information:|| Postal: http://www.elsevier.com/wps/find/supportfaq.cws_home/regional|
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Manuel Agosin & Roberto Machado, 2005.
"Foreign Investment in Developing Countries: Does it Crowd in Domestic Investment?,"
Oxford Development Studies,
Taylor & Francis Journals, vol. 33(2), pages 149-162.
- Manuel R. AGOSIN & Ricardo MAYER, 2000. "Foreign Investment In Developing Countries, Does It Crowd In Domestic Investment?," UNCTAD Discussion Papers 146, United Nations Conference on Trade and Development.
- Avinash K. Dixit & Robert S. Pindyck, 1994. "Investment under Uncertainty," Economics Books, Princeton University Press, edition 1, number 5474, March.
- Ernst R. Berndt & Rachel Glennerster & Michael R. Kremer & Jean Lee & Ruth Levine & Georg Weizsäcker & Heidi Williams, 2007. "Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness," Health Economics, John Wiley & Sons, Ltd., vol. 16(5), pages 491-511.
- Ernst R. Berndt & Rachel Glennerster & Michael Kremer & Jean Lee & Ruth Levine & Georg Weizsacker & Heidi Williams, 2006. "Advance Market Commitments for Vaccines Against Neglected Diseases: Estimating Costs and Effectiveness," CID Working Papers 127, Center for International Development at Harvard University.
When requesting a correction, please mention this item's handle: RePEc:eee:socmed:v:72:y:2011:i:2:p:202-205. See general information about how to correct material in RePEc.
If references are entirely missing, you can add them using this form.